 WEST LAFAYETTE, Ind., Sept. 22, 2021 GLOBE NEWSWIRE -- Inotiv, Inc. NASDAQ:NOTV the Company, We, Our or Inotiv, a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the pricing of its offering of 125,000,000 aggregate principal amount of 3.25 convertible senior notes due 2027 the notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended the Securities Act. The offering size was increased from the previously announced offering size of 110,000,000 aggregate principal amount of notes. The notes will be fully and unconditionally guaranteed, on a senior, unsecured basis, by BAS Evansville, Inc., a wholly owned subsidiary of Inotiv the guarantor. The issuance and sale of the notes are scheduled to settle on September 27, 2021, subject to customary closing conditions. Inotiv also granted the initial purchaser of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional 15,000,000 principal amount of notes. 